Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

CardioDx Announces The Completion Of Multicenter Validation Study For Corus CAD

CardioDx, Inc. (CardioDx), a cardiovascular genomic diagnostics company, announced that the company has successfully completed its multicenter validation study for Corus CAD, the first and only gene expression test to quantify the likelihood of obstructive coronary artery disease (CAD) in patients with stable chest pain. The company expects to present results of the study by the end of 2009, and will publish the results in 2010.

Following completion of the validation study, CardioDx has made Corus CAD available in nine states initially, with broader availability expected in 2010. The test is at present available in Kentucky, Maryland, Illinois, Washington, Wisconsin, Minnesota, North Carolina, Texas and Arizona. Patient samples are processed in Palo Alto at CardioDx’s CLIA-certified laboratory.

“Completing the validation study for Corus CAD marks a major milestone for CardioDx,” said David Levison, chief executive officer of CardioDx. “Our focus now turns to further developing the clinical and economic evidence needed to increase patient access to the unique benefits of Corus CAD.”

Corus CAD provides unique genomic information about an individual’s disease processes at the molecular and cellular levels. When this information is combined with standard clinical assessments, physicians obtain a more complete picture of their patient’s disease and can better individualize patient care.

“Our decision to develop Corus CAD was derived from many physician interactions in which they stressed the importance of and current challenges with effectively assessing obstructive CAD in patients with stable chest pain,” said Levison. “We envision that a non-invasive, objective, easy-to-use test such as Corus CAD will empower physicians to more confidently identify which of these patients may have obstructive CAD.”